COMMUNIQUÉS West-GlobeNewswire

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009
12/03/2026
- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe - - SELLAS’ Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilized - - Topline [...]
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
12/03/2026
Award recognizes leading chronic kidney disease advocates WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and [...]
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
12/03/2026
Working to advance TSC-related epilepsy program, with a focus on capital efficiency AUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ: FLNA, “Filana [...]
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
12/03/2026
PARAMUS, NJ, March 12, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage [...]
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
12/03/2026
PONTE VEDRA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today [...]
ORYZON Expands Patent Protection for Iadademstat with Grant Decision in Mexico Covering Combinations with PD-1/PD-L1 Inhibitors
12/03/2026
Key combination for the treatment of Small Cell Lung Cancer MADRID and CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical [...]
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
12/03/2026
$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics’ Vivasure [...]
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
12/03/2026
Root-Cause Attack. Chemo Sensitization. Safer Profile. MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on [...]
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
12/03/2026
CNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND submission expected in 4Q 2026 to support anticipated initial [...]
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products
12/03/2026
Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio Transaction expected to [...]
Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System
12/03/2026
Company begins roll out of innovative diabetes care HbA1c column system in Brazil Commercial leadership strengthened with key appointment DUBLIN, March 12, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a [...]
CDT Notes Sarborg Expansion into Rare Disease Signature Intelligence
12/03/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 12, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the expansion of its [...]
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
12/03/2026
Reduced progression of myocardial fibrosis measured by LGE on cardiac MRI (p=0.022) Significant improvement in LVEF versus placebo in patients with baseline cardiomyopathy (p=0.017) Global Statistical Test (GST) [...]
Pelthos Therapeutics to Present at 38th Annual ROTH Conference
12/03/2026
DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“ [...]
Easy Environmental Solutions surges to great start in first quarter of 2026
12/03/2026
Terreplenish® leads the way as company responds to worldwide nitrogen shortage MANKATO, Minn., March 12, 2026 (GLOBE NEWSWIRE) -- Easy Environmental Solutions, Inc. (OTC: EZES) entered 2026 with great momentum following [...]
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
12/03/2026
Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer (NSCLC) despite immune [...]
Centre for Neuro Skills Appoints Curtis Shipman as Chief Information Officer
12/03/2026
Technology leader brings 15+ years of experience in enterprise infrastructure, cybersecurity and digital transformation to national brain injury rehabilitation provider BAKERSFIELD, Calif., March 12, 2026 (GLOBE [...]
20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies
12/03/2026
Protein Biomarkers May Play an Important Role in Overcoming Limitations of Circulating Tumor DNA for Screening Early-Stage Cancers GAITHERSBURG, M.D., March 12, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs (Nasdaq: AIDX), an [...]
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
12/03/2026
Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated [...]

Pages